We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

47 hedge funds and large institutions have $593M invested in China Biologic Products Holdings, Inc. in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

88% more funds holding

Funds holding: 2547 (+22)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

46% more capital invested

Capital invested by funds: $407M → $593M (+$186M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.64M

Holders
47
Holders Change
+22
Holders Change %
+88%
% of All Funds
1.35%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
26
Increased
11
Reduced
7
Closed
4
Calls
Puts
$1.64M
Net Calls
-$1.64M
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$489M
VAM
2
Visium Asset Management
New York
$17.3M +$14M +343,935 +770%
Fidelity International
3
Fidelity International
Bermuda
$10M +$9.22M +225,808 New
Morgan Stanley
4
Morgan Stanley
New York
$9.05M +$7.06M +172,787 +563%
Renaissance Technologies
5
Renaissance Technologies
New York
$8.9M +$2.85M +69,725 +53%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$7.99M +$7.34M +179,600 New
EMR
7
Errol M. Rudman
$4.9M +$4.5M +110,201 New
CAM
8
Cormorant Asset Management
Massachusetts
$4.45M +$4.08M +100,000 New
LBA
9
Letko, Brosseau & Associates
Quebec, Canada
$4.31M
HSBC Holdings
10
HSBC Holdings
United Kingdom
$4.27M -$2.21M -53,992 -36%
DKCM
11
Davidson Kempner Capital Management
New York
$4.18M +$3.84M +94,045 New
William Blair & Company
12
William Blair & Company
Illinois
$3.44M +$3.16M +77,389 New
Invesco
13
Invesco
Georgia
$3.04M -$768K -18,790 -22%
Ameriprise
14
Ameriprise
Minnesota
$2.67M +$2.45M +60,000 New
BIT
15
BlackRock Institutional Trust
California
$2.64M +$61K +1,493 +3%
PHK
16
Point72 Hong Kong
Hong Kong
$2.17M +$1.99M +48,815 New
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$2.02M +$531K +13,000 +40%
GPGA
18
Grandeur Peak Global Advisors
Utah
$1.89M +$1.73M +42,439 New
GPCM
19
Granite Point Capital Management
Massachusetts
$1.56M +$1.43M +35,000 New
BA
20
BlackRock Advisors
Delaware
$1.03M +$935K +22,900 +6,815%
ACM
21
Ativo Capital Management
Illinois
$881K -$154K -3,781 -16%
SIM
22
Spark Investment Management
New York
$836K +$147K +3,600 +24%
EI
23
EAM Investors
California
$777K +$714K +17,473 New
Two Sigma Investments
24
Two Sigma Investments
New York
$777K +$714K +17,477 New
GCP
25
GSA Capital Partners
United Kingdom
$641K +$348K +8,522 +145%

CBPO Hedge Fund Activity: Q2 2014 in Review

47 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2014, worth a combined $593M — up 46% from $407M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBPO positions and 4 closed out — a net gain of 22 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Visium Asset Management, adding an estimated $14M. The largest seller was HSBC Holdings, cutting an estimated $2.21M.

  • 47 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2014, up from 25 in Q1 2014.
  • Funds reported $593M of China Biologic Products Holdings, Inc. stock for Q2 2014, up 46% quarter-over-quarter.
  • 26 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2014 and 4 closed out, a net change of +22 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q2 2014 was Visium Asset Management, an estimated $14M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q2 2014 was HSBC Holdings, an estimated $2.21M sold.

Based on aggregated 13F filings for Q2 2014.